Introduction
In recent years, conventional views regarding the phase') without apparent vasculitis. This can turn at any time into a full-blown generalized disease.1,3,4 treatment of WG have been challenged by observations on its variable clinical course.1 In 1958,
The two-phase course of WG and the increasing early identification of cases still in the initial phase Walton2 first proposed in his now classic paper that the natural history of WG has two phases, beginning due to improved diagnostic procedures, plus the recognition that WG represents a chronic-relapsing, with symptoms in the upper respiratory tract and continuing with evidence of widespread inflammanon-curable condition, provide a rationale for a stage and extent adapted therapy. tion. Later studies confirmed that WG follows a twophase course: in most patients the upper and/or Because of the potentially life-threatening course of WG, there is universal agreement that the standard lower respiratory tracts are first affected ('initial therapy of daily cyclophosphamide (CYC) plus predachieving remission by immunosuppression in generalized WG, we began a prospective study in 1986 nisone must be the first-line therapy in the majority of patients.1,5,6 This regimen, however, is toxic and combining interdisciplinary clinical evaluation, laboratory and immunological parameters of disease non-curing.5,7 Recent studies on less aggressive protocols for WG (e.g. pulse CYC or methotrexate) have extension and activity. shown success in only a special set of WG patients with non-life-threatening disease.8,9 In the 10 years since DeRemee's first observation of a beneficial Methods effect from T/S in WG patients, its use has led to conflicting results (Table 1) and much debate.10-12
Patients
However, most of the reported cases received additional immunosuppressive drugs, making it difficult Seventy-two patients fulfilling the American College of Rheumatology 1990 criteria for classification of to compare the results of the various studies and to identify the specific effect of T/S. WG13 as well as the 1992 Chapel Hill Consensus Conference definition for WG14 were studied To determine the effectiveness of T/S in treating initial phase WG and in preventing relapse after ( Figure 1 ). patients had biopsy-confirmed WG with necrotizing
Initial phase WG
vasculitis, granulomatous changes, or both in a typical Nineteen patients (5 male, 14 female) were in the organ system (34 in the upper respiratory tract, 7 in initial phase of WG at the time of diagnosis and the the lower airways, 7 in kidney). Forty-nine patients start of treatment with T/S: symptoms were restricted were positive for cANCA (PR3-ANCA). All 53 patients to the upper and/or lower airways, without constituhad received CYC as initial therapy, either as part of tional symptoms or systemic vasculitis. 15, 16 In all 19 the standard therapy (daily CYC 2-4 mg/kg) and/or as cases, biopsy samples with pathological features of pulse CYC combined with prednisone, until achieve-WG were available (necrotizing vasculitis or granuloment of complete or partial remission. At entry into matous changes). In one patient with involvement of the study, the 45 patients were divided into two the upper and lower respiratory tracts, an isolated groups: 24 patients (group A) received T/S alone as round shadow in the lung was removed and identiremission sustaining medication (2×960 mg/day) fied as a granulomatous vasculitis. All other biopsies while 21 patients (group B) were given no further were performed by an otorhinolaryngologist. The treatment. The eight patients who had mostly attained median age of patients at the time of diagnosis was only partial remission under CYC (group C) were 41 years (range 23-67 years; Table 2 ). Twelve treated with T/S plus low-dose prednisone (median patients were positive for classic anti-neutrophil daily dosage 10 mg, range 5-15mg). cytoplasmic antibodies (cANCA), which were confirmed as proteinase-3-ANCA (PR3-ANCA) in enzyme-linked immunosorbent assay (ELISA). 15 Ten Assessment of disease extent and activity of the 19 patients received T/S (2×960 mg/day) as first treatment, three patients had undergone previous All patients were examined by a team of specialists therapy with other antibiotics, or antituberculous in otorhinolaryngology, ophthalmology, etc. All agents, and four patients had been treated with patients underwent an extended imaging procedure, prednisone without induction of remission. Two including magnetic resonance imaging (MRI) scans patients had received CYC plus prednisone less than of the head, which were evaluated as described 3 months before T/S.
elsewhere.17 Comprehensive records were compiled at diagnosis, at the end of immunosuppression, every
Generalized WG
6-12 months during the study, and at completion of Fifty-three patients (25 men, 28 women) with generalthe study. ized WG were studied (Table 3) . Forty-eight of these Extent of disease was assessed using the expanded ELK classification (ear, nose and throat/lung/kidney 
Statistical analysis
(range 3-47 months). In four of these five patients, Data are reported as median values, and analysed the disease progression was observed during the first using Wilcoxon's rank test, the Mann-Whitney U year of treatment with T/S, in the fifth patient after test, and the x2 test. In all statistical tests, p<0.05 47 months. In three further non-responders, a serious was considered significant.
generalized WG developed between months 24 and 60 of T/S therapy. Six of the eight non-responders (75%) and six of the 11 responders (54%) were positive for cANCA (no significant difference).
Results

Initial phase WG Sustaining remission in generalized WG
Eleven of 19 patients (58%) with initial phase WG responded to T/S with complete (n=6) or partial Ten out of 24 patients (42%) treated with T/S alone (group A) to sustain remission after immunosuppres-(n=5) remission lasting a median time of 43 months (range 6-88 months) (Figure 2) . The eight nonsion suffered a relapse after a median 13 months (range 5-58 months). By comparison, of the 21 responders (42%) showed disease progression during T/S therapy, and treatment had to be stopped after a patients receiving no further treatment (group B), six (29%) experienced relapse after a median 22.5 median period of 17 months (range 3-60 months). In five non-responders, local disease progression (in months (range 18-26 months) (Figure 3 ). There were no significant differences between groups A and B the upper respiratory tract) required discontinuation in the type and duration of previous immunosuppressive therapy, in time enrolled in the study, in the Table 4 ). In all three groups, the clinical features at extent and pattern of organ involvement and in the relapse as measured by the DEI were generally less levels of cANCA, sIL2-R, and C-reactive protein at severe than at initial presentation (Table 4) . The diagnosis or at entry into the study (Table 3) . In all, median cANCA titre in patients experiencing relapse eight patients treated with combined T/S and lowincreased from 8 to 16 in group A, from 4 to 16 in dose prednisone (median daily dosage 10mg, range group B, and from 16 to 32 in group C (Table 4) . 5-15mg; group C) relapse was noted between 2 and 24 months.
Side-effects
Analysis of medical records to identify the characteristics of patients with relapses (Table 4) revealed Side-effects attributable to T/S were seen in 10/51 differences in the response to the previous immunopatients (mild leucopenia in 6, an mild increase of suppressive agents, but no differences in the treatcreatinine level in 5, an eosinophilia and an increase ment protocols. Most of the patients were treated of lever enzymes in one). In three patients, a combefore entry into this study with CYC, either as part bination of leucopenia and elevated creatinine level of the standard regimen or applied in pulses concomwas observed. T/S side-effects required the cessation itant with prednisone. There was a greater tendency of T/S in three patients who had been in complete towards a higher median DEI score at entry into the remission until that time. study in patients who suffered a later relapse than in patients who remained free of relapse (group A: 1 vs. 0; group B: 2 vs. 0; group C: 3, no patients free Discussion of relapse, see Table 4 ).
In patients suffering a relapse, median DEI score Since DeRemee first described a therapeutic benefit from T/S in treating WG in 1985, it has been applied increased from 1 at entry to 5 at the time of relapse in group A, from 2 at entry to 6 at relapse in group in numerous single cases and in a number of small trials. The disparate results of these studies have B, and from 3 to 5.5 in group C (Figure 3 and 
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12 (86) 6 (100) 14 ( generated much debate.10-12 Most of the studies, cipal therapy in a patient with generalized WG and subsequent renal involvement.21 Under T/S, complete however (Table 1) , applied T/S in combination with other drugs, usually CYC and/or prednisone. Until remission was attained for a period of 9 months in this patient. Although other authors achieved tempornow, no large study applying a uniform design has assessed the specific effect of T/S. ary improvement in patients with generalized WG, this was usually followed by severe relapse with In the present study, T/S monotherapy induced complete or partial remission lasting a median of 43 multi-organ involvement.26,27
In patients with generalized WG, T/S appears to months (max. 88 months) in 11/19 patients (58%) with initial phase WG. In 8/19 patients (42%) with be equally inappropriate for inducing remission and for sustaining remission already attained by prior initial phase WG, T/S therapy had to be discontinued due to lack of response. In five of these eight nonimmunosuppression. Under T/S monotherapy (group A), relapse occurred in 42% of patients, whereas in responders, disease progression in the ENT area required termination of therapy after a median 7 the control group (group B) receiving no therapy of any form, only 29% of patients suffered relapse. The months. Three patients with initial phase WG developed severe generalized disease between the two groups did not differ significantly with respect to disease manifestations at diagnosis and at entry second and fifth years of T/S therapy after initial complete or partial remission. The literature reports into the study, duration and type of previous immunosuppression, or length of time in the study. T/S therapy in a total of 17 patients with initial phase WG (symptoms confined exclusively to the upper All of the patients with generalized WG mostly in only partial remission after CYC (group C) suffered and lower respiratory tracts with no general symptoms or clinical signs of vasculitis) relapse within 24 months under a regimen of T/S plus low-dose prednisone. The literature contains (Table 1) .10,20,22-24,27 Nine of these 17 patients received no further medication for induction of little information on the administration of T/S to sustain remission in generalized WG. Israel et al. remission, while three received T/S in addition to immunosuppressive therapy. In the remaining five used T/S in seven patients who had achieved only partial remission of generalized WG and noted patients24 the concomitant medication was not reported. Long-term remission was achieved with T/S subsequent relapse in five. 22 In 1983, Fauci et al.6 postulated a possible cure for WG using the 'standard therapy in 10 of these 17 patients. The 59% rate of response in these patients is surprisingly similar to therapy'. Today, however, opinion holds that WG is a chronic-relapsing, non-curable condition. Gordon our own rate of 58%. However, our median followup time of 43 months (max. 88 months) is clearly et al.,7 for example, observed relapse in 13/28 patients (44%) with previously generalized WG after longer than the median 12-month period in these patients (range 2-48 months). Moreover, none of a median of 42 months. Some of the patients were therapy-free and some were undergoing immunoour patients received any additional medication.
In light of the similar favourable rates of response suppressive therapy (CYC, prednisone, azathioprine) at the time of relapse. Like us, these authors found in our own and other studies, plus the lack of serious side-effects, we think T/S represents a viable alternatno association between the rate of relapse and the duration and prior dosage of CYC. In a study of 158 ive to standard immunosuppression with CYC plus prednisone for inducing remission in patients with patients, Hoffman et al.5 found that 50% of remissions were followed by one or more relapses. initial phase WG. We say this even in the absence of studies using placebo controls, and although the In our patients, the extent of disease was less at relapse than it had been at diagnosis. The DEI score mechanism responsible for the effects of T/S (other antibiotics have no comparable benefit in WG) in group A was 5 at relapse vs. 9 at diagnosis, in group B 6 vs. 9, and in group C 5.5 vs. 8. Gordon remains largely unknown.10-12,26,29 In applying T/S therapy in initial phase WG, it is important et al. found the clinical picture in his patients at relapse to resemble that at presentation, but with that systemic disease manifestations are regularly excluded by interdisciplinary examinations for timely less extensive disease at relapse and, occasionally, entirely new organ manifestations.7 detection of local destruction and to meet the everpresent danger of transition to a generalized form of We found no statistically confirmed factors predictive of relapse. Still, patients suffering subsequent WG. At present, no clinical, serological or immunological factors predictive of subsequent course in relapse were less likely to have attained complete remission under previous immunosuppression than WG are known.
In the few reports on T/S therapy in patients with their non-relapsing counterparts. The DEI score at entry into the study of these patients was on average generalized WG (Table 1) , T/S was usually applied in addition to immunosuppression with CYC and/or higher (median DEI >0) than in patients without relapse (median DEI=0). The concomitant adminisprednisone, thus masking the specific effect of T/S.10,19,21,22,24-28 Only Spiera used T/S as the printration of prednisone brought no additional benefit: all patients receiving combined T/S and low-dose combined with low-dose prednisone are effective in sustaining remission in once generalized WG. prednisone (group C) experienced relapse. Their DEI Since the introduction of 'standard therapy' as score at start of study was higher (median DEI=3) first-line treatment, future therapeutic studies will compared to patients of group A and B (median focus increasingly on long-term follow-up, rates DEI=0). Apparently, patients with 'smouldering' of relapse, and on identifying factors predictive of disease activity are at greater risk of relapse than future course. patients in complete remission. This is also supported by the high rate of relapse under T/S therapy (5/7 patients) noted by Israel, all of whom were in only partial remission at the outset of treatment.22
